SCHEMBL15031616

SCHEMBL15031616

COC(=O)c1cc(-c2ccc(-c3cnn4c(N)c(C(C)=O)c([C@H]5CC[C@@](O)(CO)CC5)nc34)cn2)ccc1OC

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RET P07949 8/20 0.36
▸ KIF5B P33176 8/20 0.36
▸ KDR P35968 8/20 0.36
▸ LCK P06239 4/20 0.36
▸ CSF1R P07333 3/20 0.36
▸ LYN P07948 3/20 0.36
▸ PDGFRB P09619 3/20 0.36
▸ FGR P09769 3/20 0.36
▸ KIT P10721 3/20 0.36
▸ SRC P12931 3/20 0.36
▸ PDGFRA P16234 3/20 0.36
▸ FGFR2 P21802 3/20 0.36
▸ BLK P51451 3/20 0.36
▸ ABL1 P00519 2/20 0.36
▸ NPM1 P06748 2/20 0.36
▸ BCR P11274 2/20 0.36
▸ FLT3 P36888 2/20 0.36
▸ SYK P43405 2/20 0.36
▸ ALK Q9UM73 2/20 0.36
▸ JAK2 O60674 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15007087 1.00 RET (0.36) RETKIF5BKDRLCKCSF1R
SCHEMBL15007088 1.00 RET (0.36) RETKIF5BKDRLCKCSF1R
SCHEMBL25308 0.94 RET (0.35) RETKIF5BKDRLCKCSF1R
SCHEMBL17836374 0.94 RET (0.35) RETKIF5BKDRLCKCSF1R
SCHEMBL15007159 0.89 AKT1 (0.36) RETKIF5BKDRLCKSRC
SCHEMBL15006923 0.87 PIK3CA (0.42) MTORPIK3CA
SCHEMBL17836462 0.85 RAB9A (0.34) RETKIF5BKDRLCKCSF1R
SCHEMBL21487 0.84 MTOR (0.42) RETKIF5BKDRETV6CCDC6
SCHEMBL15007234 0.84 MTOR (0.42) RETKIF5BKDRETV6CCDC6
SCHEMBL20915 0.84 MTOR (0.42) RETKIF5BKDRETV6CCDC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883801-B2 Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors MERCK SHARP & DOHME CORP. (US) 2014-11-11 — — US disclosed
US-8883801-B2 Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors MERCK SHARP & DOHME CORP. (US) 2014-11-11 — — US disclosed
US-20130150362-A1 NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MERCK SHARP & DOHME CORP. (US) 2013-06-13 — — US disclosed
US-20130150362-A1 NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MERCK SHARP & DOHME CORP. (US) 2013-06-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130150362-A1 NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MTOR, RPS6KA5, PAK5 RET 498/4885KIF5B 4268/4885KDR 1726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback